Original language | English (US) |
---|---|
Pages (from-to) | 413-446 |
Number of pages | 34 |
Journal | The Lancet |
Volume | 396 |
Issue number | 10248 |
DOIs | |
State | Published - Aug 8 2020 |
ASJC Scopus subject areas
- Medicine(all)
Access to Document
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Dementia prevention, intervention, and care : 2020 report of the Lancet Commission. / Livingston, Gill; Huntley, Jonathan; Sommerlad, Andrew; Ames, David; Ballard, Clive; Banerjee, Sube; Brayne, Carol; Burns, Alistair; Cohen-Mansfield, Jiska; Cooper, Claudia; Costafreda, Sergi G.; Dias, Amit; Fox, Nick; Gitlin, Laura N.; Howard, Robert; Kales, Helen C.; Kivimäki, Mika; Larson, Eric B.; Ogunniyi, Adesola; Orgeta, Vasiliki; Ritchie, Karen; Rockwood, Kenneth; Sampson, Elizabeth L.; Samus, Quincy; Schneider, Lon S.; Selbæk, Geir; Teri, Linda; Mukadam, Naaheed.
In: The Lancet, Vol. 396, No. 10248, 08.08.2020, p. 413-446.Research output: Contribution to journal › Review article › peer-review
}
TY - JOUR
T1 - Dementia prevention, intervention, and care
T2 - 2020 report of the Lancet Commission
AU - Livingston, Gill
AU - Huntley, Jonathan
AU - Sommerlad, Andrew
AU - Ames, David
AU - Ballard, Clive
AU - Banerjee, Sube
AU - Brayne, Carol
AU - Burns, Alistair
AU - Cohen-Mansfield, Jiska
AU - Cooper, Claudia
AU - Costafreda, Sergi G.
AU - Dias, Amit
AU - Fox, Nick
AU - Gitlin, Laura N.
AU - Howard, Robert
AU - Kales, Helen C.
AU - Kivimäki, Mika
AU - Larson, Eric B.
AU - Ogunniyi, Adesola
AU - Orgeta, Vasiliki
AU - Ritchie, Karen
AU - Rockwood, Kenneth
AU - Sampson, Elizabeth L.
AU - Samus, Quincy
AU - Schneider, Lon S.
AU - Selbæk, Geir
AU - Teri, Linda
AU - Mukadam, Naaheed
N1 - Funding Information: AS reports grants from Wellcome Trust (200163/Z/15/Z), outside the submitted work. DA reports grants from Eli Lilly, during the conduct of the study. CBa reports grants and personal fees from Aca-dia and Lundbeck; and personal fees from Roche, Otsuka, Biogen, Eli Lilly, and Pfizer, outside the sub-mitted work. SB reports grants and personal fees from AbbVie, personal fees and non-financial sup-port from Eli Lilly, and personal fees from Eleusis, Daval International, Boehringer Ingelheim, Axovant Sciences, Lundbeck, and Nutricia, outside the submitted work; and he has been employed by the Department of Health for England. NF reports non-financial support from Eli Lilly, outside the submitted work. LNG and her institutions (Johns Hopkins University, Baltimore, MD, USA, Drexel University, Philadelphia, PA, USA, and Thomas Jefferson University, Philadelphia, PA, USA) are entitled to receive royalties from fees associated with online training for the tailored activity program, which is an evidence-based program referenced in the Review. RH reports grants from Department of Health, NIHR HTA Programme, outside the submitted work; and he is a Scientific Trustee of the charity Alzheimer's Research UK. MK reports grants from the UK Medical Research Council (S011676, R024227), NordForsk (the Nordic Programme on Health and Welfare, 75021) and the Academy of Finland (311492), outside the submitted work. EBL reports other (royalties) from UpToDate, outside the submitted work. KRo reports personal fees from Clinical Cardio Day-Cape Breton University, Sydney, NS, Canada, CRUIGM-Montreal, Jackson Laboratory, Bar Harbor, MA, USA (speaker fees), MouseAge, Rome, Italy (speaker fees), Lundbeck, Frontemporal Dementia Study-Group, SunLife Insurance, Japan, outside the submitted work. He is a President and Chief Science Officer of DGI Clinical, which in the last 5 years has contracts with pharma and device manufacturers (Baxter, Baxalta, Shire, Hollister, Nutricia, Roche, Otsuka) on individualised outcome measurement. In 2017, he attended an advisory board meeting with Lundbeck. He is also Associate Director of the Canadian Consortium on Neurodegeneration in Aging, which is funded by the Canadian Institutes of Health Research, and with additional funding from the Alzheimer Society of Canada and several other charities, as well as, in its first phase (2013-2018), from Pfizer Canada and Sanofi Canada. He receives career support from the Dalhousie Medical Research Foundation as the Kathryn Allen Weldon Professor of Alzheimer Research, and research support from the Canadian Institutes of Health Research, the QEII Health Science Centre Foundation, the Capital Health Research Fund and the Fountain Family Innovation Fund of the QEII Health Science Centre Foundation. LSS reports grants and personal fees from Eli Lilly, Merck, and Roche/Genentech; personal fees from Avraham, Boehringer Ingelheim, Neurim, Neuronix, Cognition, Eisai, Takeda, vTv, and Abbott; and grants from Biogen, Novartis, Biohaven, and Washington University DIAN-TU, outside the submitted work. The remaining authors declare no conflict of interests. Funding Information: We are partnered by University College London (UCL), the Alzheimer's Society, UK, the Economic and Social Research Council, and Alzheimer's Research UK, and would like to thank them for financial help. These organisations funded the fares, accommodation, and food for the Commission meeting but had no role in the writing of the manuscript or the decision to submit it for publication. We would like to thank Bernadette Courtney, Jacques Gianino, and Nuj Monowari, from UCL, London, UK, for their administrative help, including managing finances, booking rooms and food, and setting up a website supported by the University College London Hospitals National Institute for Health Research Biomedical Research Centre. We would like thank Henrik Zetterberg for advice on biomarkers and dementia.
PY - 2020/8/8
Y1 - 2020/8/8
UR - http://www.scopus.com/inward/record.url?scp=85089068138&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85089068138&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(20)30367-6
DO - 10.1016/S0140-6736(20)30367-6
M3 - Review article
C2 - 32738937
AN - SCOPUS:85089068138
VL - 396
SP - 413
EP - 446
JO - The Lancet
JF - The Lancet
SN - 0140-6736
IS - 10248
ER -